Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
NL-OMON47798Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Adverse events assessment. Started May 2013; status: active, not recruiting.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47798.